Jump to content

Prazosin

From Wikipedia, the free encyclopedia

Prazosin
Clinical data
Trade namesMinipress, others
AHFS/Drugs.comMonograph
MedlinePlusa682245
License data
Pregnancy
category
Routes of
administration
By mouth
Drug classα1 blocker
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~60%
Protein binding97%[4]
Onset of action30–90 minutes[5]
Elimination half-life2–3 hours[4]
Duration of action10–24 hours[4]
Identifiers
  • [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2-furyl)methanone
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.038.971 Edit this at Wikidata
Chemical and physical data
FormulaC19H21N5O4
Molar mass383.408 g·mol−1
3D model (JSmol)
  • O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)c4occc4
  • InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22) checkY
  • Key:IENZQIKPVFGBNW-UHFFFAOYSA-N checkY
  (verify)

Prazosin Hydrochloride, commonly referred to as simply prazosin, and sold under various brand names, is an alpha-adrenergic receptor blocking agent (α1 blocker) medication.[6] Prazosin is most commonly used to lower high blood pressure, or to treat symptoms of an enlarged prostate. Prazosin is also often used as an off-label medication, as a nightmare preventative for those with post-traumatic stress disorder (PTSD).[6] Other uses may include heart failure and Raynaud syndrome.[7] Prazosin is currently considered a less-preferred treatment for high blood pressure.[6] Prazosin is available in tablet form, and is administered orally.[6] In the United States it is a prescription medication, requiring a doctor's order at a pharmacy.

Prazosin is a non-selective inverse agonist of the α1-adrenergic receptors.[6] It works to decrease blood pressure by dilating blood vessels and helps with an enlarged prostate by relaxing the outflow of the bladder.[6] How it works in PTSD is not entirely clear.[6] Common side effects include dizziness, sleepiness, nausea, and heart palpitations.[6] Serious side effects may include low blood pressure with standing and depression.[6][7]

Prazosin was patented in 1965 and came into medical use in 1974.[8] It is available as a generic medication.[6] In 2021, it was the 183rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.[9][10]

Medical uses

[edit]

Prazosin is typically administered three times daily for hypertension or urinary symptoms associated with an enlarged prostate.[6]

High blood pressure

[edit]

Prazosin is active when taken orally and has minimal effects on cardiac function due to its selectivity for α1-adrenergic receptors. It lowers blood pressure by relaxing and dilating blood vessels. When treatment is initiated, heart rate and cardiac contractility may increase reflexively to compensate for the reduction in blood pressure. With continued treatment, these compensatory responses diminish, and blood pressure decreases.

Prazosin's antihypertensive properties make it a second-line treatment for high blood pressure.[11]

Enlarged prostate

[edit]

Prazosin is also used to treat urinary hesitancy associated with benign prostatic hyperplasia. It blocks α1-adrenergic receptors, thereby relaxing smooth muscle in the prostate, urethra, and bladder outlet to improve urinary flow.[6] Although not a first-line treatment for either hypertension or benign prostatic hyperplasia, it may be useful in patients with both conditions.[11]

PTSD

[edit]

In the 1990s, Murray A. Raskind and colleagues observed that prazosin appeared to reduce nightmares in military veterans receiving treatment for urinary hesitancy. Subsequent systematic reviews and meta-analyses have found that prazosin can improve sleep quality and reduce nightmares associated with post-traumatic stress disorder (PTSD).[12][13]

The mechanism by which prazosin reduces PTSD-related nightmares is not fully understood. It is thought to cross the blood–brain barrier and block the effects of norepinephrine at α1-adrenergic receptors in the brain,[14] thereby reducing the heightened adrenergic activity associated with fear and arousal.[15] Prazosin has been described as an inverse agonist at α1-adrenergic receptors.[16] These receptors are expressed on dendrites of neurons receiving noradrenergic input. Some noradrenergic pathways in the central nervous system contribute to the ascending reticular activating system, which promotes arousal when stimulated.[17][18]

Clinical trial results have been mixed. Although some studies have found prazosin effective for PTSD-related nightmares, particularly in non-military populations, a large randomized trial involving military veterans with chronic PTSD found no significant improvement in distressing dreams or sleep quality compared with placebo.[19]

The 2023 United States Department of Veterans Affairs and Department of Defense (VA/DoD) Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder issued a "weak against" recommendation for prazosin in the treatment of overall PTSD symptoms (Recommendation 18). However, it issued a "weak for" recommendation for prazosin specifically for the treatment of PTSD-related nightmares (Recommendation 32).[20]

For PTSD-related nightmares, prazosin is generally administered once daily at bedtime. Although it is not a sedative, it may be prescribed as an adjunct to other medications used to treat PTSD.[15]

Antivenom

[edit]

The drug is also used for severe stings from the Indian red scorpion.[21][22]

Adverse effects

[edit]

Common (4–10% frequency) side effects of prazosin include dizziness, headache, drowsiness, fatigue, weakness, palpitations, and nausea.[3] Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, edema, orthostatic hypotension, dyspnea, syncope, vertigo, depression, anxiety, nasal congestion, and rash.[3] A very rare side effect of prazosin is priapism.[3][23] One phenomenon associated with prazosin is known as the "first-dose response", in which the side effects of the drug—specifically orthostatic hypotension, dizziness, and drowsiness—are especially pronounced in the first dose.[3]

Orthostatic hypotension and syncope are associated with the body's poor ability to control blood pressure without active α-adrenergic receptors. The nasal congestion is exacerbated by changing body positions, because α1-adrenergic receptors also control nasal vascular blood flow and alpha blockers inhibit this, in the same way that alpha-adrenergic agonists have the opposite effect of being a decongestant.[24][25]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Prazosin is an α1-blocker that acts as a non-selective inverse agonist at α1-adrenergic receptors, including of the α1A-, α1B-, and α1D-adrenergic receptor subtypes.[26] It binds to these receptors with affinity (Ki) values of 0.13 to 1.0 nM for the α1Α-adrenergic receptor, 0.06 to 0.62 nM for the α1B-adrenergic receptor, and 0.06 to 0.38 nM for the α1D-adrenergic receptor.[27][28] It has much lower affinity for the α2-adrenergic receptors (Ki = 210–5,012 nM for the α2A-adrenergic receptor, 13–676 nM for the α2B-adrenergic receptor, and 10–257 nM for the α2C-adrenergic receptor).[27][28][29] The α1-adrenergic receptors are found in vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine.[30] They are also found throughout the central nervous system.[31] α1-Adrenergic receptors have additionally been found on immune cells, where catecholamine binding can stimulate and enhance cytokine production.[32][33]

Pharmacokinetics

[edit]

Prazosin has an onset of action of 30 to 90 minutes,[5] the elimination half-life of prazosin is 2 to 3 hours,[4] and its duration of action is 10 to 24 hours.[4]

History

[edit]

Prazosin hydrochloride was synthesized and developed by the Medicinal Chemistry Laboratories of Pfizer,[34] and was patented in 1965 by Pfizer. It was approved by the U.S. Food and Drug Administration as a patented medication, Minipress, in June, 1976.[35] Pfizer's patent expired in May, 1989,[36] and generic prazosin hydrochloride, as well as numerous other brand name versions of prazosin, entered the market thereafter.

Research

[edit]

Insomnia

[edit]

Prazosin has been said to be the only selective α1-adrenergic receptor antagonist which has been used in the treatment of insomnia to any significant degree.[37] It is used at doses of 1 to 12 mg for this purpose.[37] The combination of prazosin and the beta blocker timolol may produce greater sedative effects than either of them alone.[16]

Cytokine storm

[edit]

Prazosin has been shown to prevent death in animal models of cytokine storm.[38] As a repurposed drug, prazosin is being investigated for the prevention of cytokine storm syndrome and complications of COVID-19 where it is thought to decrease cytokine dysregulation.[39][33][40]

See also

[edit]

References

[edit]
  1. ↑ "Prazosin (Minipress) Use During Pregnancy". Drugs.com. 26 November 2019. Retrieved 30 January 2020.
  2. ↑ "Hypovase Tablets 0.5mg - Summary of Product Characteristics (SmPC)". (emc). 26 April 2021. Retrieved 5 February 2023.
  3. 1 2 3 4 5 "Minipress- prazosin hydrochloride capsule". DailyMed. 19 July 2021. Retrieved 5 February 2023.
  4. 1 2 3 4 5 "Prazosin". drugs.com. Retrieved 15 March 2020.
  5. 1 2 Packer M, Meller J, Gorlin R, Herman MV (March 1979). "Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure". Circulation. 59 (3): 531–539. doi:10.1161/01.cir.59.3.531. PMID 761333.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 "Prazosin Monograph for Professionals". Drugs.com. Retrieved 18 October 2026.
  7. 1 2 British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 766. ISBN 978-0-85711-338-2.
  8. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 978-3-527-60749-5.
  9. ↑ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  10. ↑ "Prazosin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  11. 1 2 Shen H (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 13. ISBN 978-1-59541-101-3.
  12. ↑ Zhang Y, Ren R, Sanford LD, Yang L, Ni Y, Zhou J, et al. (March 2020). "The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis". Sleep Medicine. 67: 225–231. doi:10.1016/j.sleep.2019.06.010. PMC 6986268. PMID 31972510.
  13. ↑ Reist C, Streja E, Tang CC, Shapiro B, Mintz J, Hollifield M (August 2021). "Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis". CNS Spectrums. 26 (4): 338–344. doi:10.1017/S1092852920001121. PMID 32362287. S2CID 218492349.
  14. ↑ Hudson SM, Whiteside TE, Lorenz RA, Wargo KA (2012). "Prazosin for the treatment of nightmares related to posttraumatic stress disorder: a review of the literature". The Primary Care Companion for CNS Disorders. 14 (2) PCC.11r01222. doi:10.4088/PCC.11r01222. PMC 3425466. PMID 22943034.
  15. 1 2 Herink KJ (25 June 2024). A 3-Times-Daily Dosing Scheme of Prazosin to Treat Posttraumatic Stress Disorder–Induced Psychological Distress in the Hospital. Psychiatrist.com (Report). doi:10.4088/pcc.23cr03696.
  16. 1 2 Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery". Pharmacological Reviews. 70 (2): 197–245. doi:10.1124/pr.117.014381. PMID 29487083. S2CID 3578916.
  17. ↑ Iwańczuk W, Guźniczak P (2015). "Neurophysiological foundations of sleep, arousal, awareness and consciousness phenomena. Part 1". Anaesthesiology Intensive Therapy. 47 (2): 162–167. doi:10.5603/AIT.2015.0015. PMID 25940332.
  18. ↑ Malenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). "Chapter 13: Sleep and Arousal". Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (3rd ed.). McGraw-Hill Medical. p. 521. ISBN 978-0-07-182770-6.
  19. ↑ Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, et al. (February 2018). "Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans". The New England Journal of Medicine. 378 (6). Massachusetts Medical Society: 507–517. doi:10.1056/NEJMoa1507598. PMID 29414272.
  20. ↑ VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (PDF) (Report). 4.0. U.S. Department of Veterans Affairs and U.S. Department of Defense. 2023. pp. 37–38.
  21. ↑ Bawaskar HS, Bawaskar PH (2008). "Scorpion sting: A study of the clinical manifestations and treatment regimes". Current Science. 95 (9): 1337–1341. JSTOR 24103245.
  22. ↑ Pandi K, Krishnamurthy S, Srinivasaraghavan R, Mahadevan S (June 2014). "Efficacy of scorpion antivenom plus prazosin versus prazosin alone for Mesobuthus tamulus scorpion sting envenomation in children: a randomised controlled trial". Archives of Disease in Childhood. 99 (6): 575–580. doi:10.1136/archdischild-2013-305483. PMID 24550184. S2CID 37215729.
  23. ↑ Bhalla AK, Hoffbrand BI, Phatak PS, Reuben SR (October 1979). "Prazosin and priapism". British Medical Journal. 2 (6197): 1039. doi:10.1136/bmj.2.6197.1039. PMC 1596841. PMID 519276.
  24. ↑ Riechelmann H, Krause W (1 January 1994). "Autonomic regulation of nasal vessels during changes in body position". European Archives of Oto-Rhino-Laryngology. 251 (4): 210–213. doi:10.1007/BF00628425. PMID 7917253. S2CID 24405406.
  25. ↑ Johnson DA, Hricik JG (1993). "The pharmacology of alpha-adrenergic decongestants". Pharmacotherapy. 13 (6 Pt 2): 110S–115S, discussion 143S–146S. doi:10.1002/j.1875-9114.1993.tb02779.x. PMID 7507588. S2CID 70981730.
  26. ↑ "Prazosin: Biological activity". IUPHAR. International Union of Basic and Clinical Pharmacology. Retrieved 3 June 2016.
  27. 1 2 "Prazosin". DrugBank.
  28. 1 2 "Prazosin Ligand page". IUPHAR/BPS Guide to PHARMACOLOGY.
  29. ↑ Proudman R, Akinaga J, Baker JG (February 2022). "The affinity and selectivity of α-adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors". Pharmacology Research & Perspectives. 10 (2) e00936. doi:10.1002/prp2.936. PMC 8882856. PMID 35224877.
  30. ↑ "Prazosin: Clinical data". IUPHAR. International Union of Basic and Clinical Pharmacology. Retrieved 3 June 2016.
  31. ↑ Day HE, Campeau S, Watson SJ, Akil H (July 1997). "Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord". Journal of Chemical Neuroanatomy. 13 (2): 115–139. doi:10.1016/S0891-0618(97)00042-2. PMID 9285356. S2CID 28007564.
  32. ↑ Heijnen CJ, Rouppe van der Voort C, Wulffraat N, van der Net J, Kuis W, Kavelaars A (December 1996). "Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis". Journal of Neuroimmunology. 71 (1–2): 223–226. doi:10.1016/s0165-5728(96)00125-7. PMID 8982123. S2CID 53151786.
  33. 1 2 Konig MF, Powell M, Staedtke V, Bai RY, Thomas DL, Fischer N, et al. (July 2020). "Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists". The Journal of Clinical Investigation. 130 (7): 3345–3347. doi:10.1172/JCI139642. PMC 7324164. PMID 32352407.
  34. ↑ Kostek LJ (1 January 1990). "Prazosin Hydrochloride". In Florey K, Al-Badr AA, Forcier GA, Brittain HG (eds.). Analytical Profiles of Drug Substances. Vol. 18. Academic Press. pp. 351–378. doi:10.1016/S0099-5428(08)60676-0.
  35. ↑ "Delving into the Latest Updates on Prazosin Hydrochloride with Synapse". synapse.patsnap.com. Retrieved 18 October 2026.
  36. ↑ Sheet TP (17 August 1987). "Pfizer's Procardia (Nifedipine) ORAL Delivery System Patent". Insights. Insights. Retrieved 18 October 2026.
  37. 1 2 Krystal AD (December 2015). "New Developments in Insomnia Medications of Relevance to Mental Health Disorders". The Psychiatric Clinics of North America. 38 (4): 843–860. doi:10.1016/j.psc.2015.08.001. PMC 5972036. PMID 26600112.
  38. ↑ Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, et al. (December 2018). "Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome". Nature. 564 (7735): 273–277. Bibcode:2018Natur.564..273S. doi:10.1038/s41586-018-0774-y. PMC 6512810. PMID 30542164.
  39. ↑ "Preventing 'Cytokine Storm' May Ease Severe COVID-19 Symptoms". HHMI.org. Retrieved 24 May 2020.
  40. ↑ Clinical trial number NCT04365257 for "Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)" at ClinicalTrials.gov